spacer
home > ebr > Winter 2009
PUBLICATIONS

European Biopharmaceutical Review

ebr
Winter 2009
At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR
   
Text
PDF
bullet
BioFinance and Management
Independent consultant Emile Bellott looks at the changing biotech landscape in light of the global financial crisis and considers the likely implications for the global pharmaceutical/biotech industry  
view
download pdf
Mark B Hassenplug and Kai Gindner at Ernst & Young examine ways in which pharmaceutical companies can maintain standards in supply chain management  
view
download pdf
bullet
BioBusiness Development
Pharma and biotech companies often manage scientific assets and equipment on their own. Bob Moore at GE Healthcare discusses why and how outsourcing scientific asset services can help to improve effectiveness in the lab  
view
download pdf
Catherine D’Arcy at PA Consulting Group describes the requirement for greater efficiency and effectiveness in R&D operations and how working closely with a global pharmaceutical company has prompted a review of key functions  
view
download pdf
Richard Barratt at Barratt Legal examines the proliferation of outsourcing operational practices in the industry, and tells us how to get the best out of it  
view
download pdf
bullet
BioResearch and Innovation
Mats Hellström and Björn Frendéus at BioInvent International examine the developments that are occurring in monoclonal antibody drugs, and discuss their future in the fight against cancer  
view
download pdf
Birgit Jehn at QIAGEN GmbH gives an overview on HLA-Typing or pre-therapeutic testing in AIDS patients  
view
download pdf
bullet
Discovery Technology
David Bunton and Lee Rankin at Biopta Ltd and Alistair Corbett at Glasgow Caledonian University discuss opioid receptors as drug targets in gastrointestinal disorders  
view
download pdf
Graham Lappin at Xceleron argues that microdosing can provide important information about a drug’s behaviour before Phase I, thereby reducing the likelihood of costly failures at a later stage  
view
download pdf
bullet
BioDevelopment and Regulatory
Ulrich Braumann at Bruker BioSpin and Herbert Thiele at Bruker Daltonik analyse structure verification of small molecules using integrated MS spectrometry and NMR spectroscopy  
view
download pdf
Josep Prous at Thomson Reuters introduces biomarkers, identifying them as a crucial factor in the evolution of drug research and development  
view
download pdf
LABALisette Oversteegen at Datamonitor discusses combination product market trends in the respiratory drug sector  
view
download pdf
bullet
BioFormulation and Manufacturing
R Keith Williams at The Clinical Biotechnology Centre, Bristol Institute for Transfusion Sciences, NHS Blood and Transplant and Angela Osborne of eXmoor pharma concepts ltd discuss small-scale biomanufacturing for clinical trials, cell and gene therapies in the UK market  
view
download pdf
Kate Westwell and Gina Wenham at Eden Biodesign explain how implementing the quality cycle can deliver product value  
view
download pdf
bullet
BioRegional
Jacques Lhomel of Biocitech tells how one of Europe’s high-profile life science parks has boosted resources for life sciences R&D  
view
download pdf
   
spacer


Published quarterly in
January, April,
July, and October

News and Press Releases

Gerresheimer AG and Stevanato Group present EZ-fill Smart™, a new and innovative Ready-To-Fill Vial Platform Gerresheimer AG and Stevanato Group present EZ-fill Smart™, a new and innovative Ready-To-Fill Vial Platform

Two leading companies introduce EZ-fill Smart™, the new Ready-To-Fill solution platform for the global vial market. Customers benefit from reduced Total Cost of Ownership, lower process complexity and accelerated speed to market. The new platform ensures higher product quality and enhanced process sustainability by introducing an alternative sterilization method.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: Summary of Year 2013

Synergy Research Group

Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement